Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Read UMR's Statement on the House Appropriations Committee's Passage of FY23 Labor-HHS Funding Bill
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Rheumatoid arthritis drug combined with standard of care may help reduce mortality for hospitalized COVID-19 patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

The study, led by principal investigators E. Wesley Ely, MD, MPH, Grant Liddle Professor of Medicine at Vanderbilt University Medical Center, and Vince Marconi, MD, of Emory University, included 1,525 hospitalized patients on supplemental oxygen from 101 centers across 12 countries in Asia, Europe, North America and South America.